-+ 0.00%
-+ 0.00%
-+ 0.00%

BioNTech to Present First Phase 2 Data on Pumitamig Plus Docetaxel in Metastatic Lung Cancer at ESMO

PUBT·10/19/2026 10:46:03
Listen to the news
BioNTech to Present First Phase 2 Data on Pumitamig Plus Docetaxel in Metastatic Lung Cancer at ESMO
  • BioNTech will present new oncology trial data at the ESMO Congress in Madrid, Oct. 23-27, 2026.
  • Phase 2 results for pumitamig combined with elfetabart drozuntecan showed preliminary antitumor activity across advanced solid tumors, with manageable safety.
  • The combination showed minimal overlapping toxicities, supporting pumitamig's potential role as a backbone for combination treatments.
  • First Phase 2 results for pumitamig with docetaxel in previously treated metastatic non-small cell lung cancer will be presented Oct. 25.
  • Separate Phase 2 data showed preliminary antitumor activity with manageable safety for pumitamig with chemotherapy in previously treated, unresectable neuroendocrine neoplasms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190645PRIMZONEFULLFEED1001278656) on October 19, 2026, and is solely responsible for the information contained therein.